Bevacizumab and Temsirolimus in Treating Patients With Recurrent or Persistent Endometrial Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

53

Participants

Timeline

Start Date

September 30, 2008

Primary Completion Date

July 15, 2011

Study Completion Date

January 25, 2016

Conditions
Recurrent Endometrial Carcinoma
Interventions
BIOLOGICAL

bevacizumab

Given IV

DRUG

temsirolimus

Given IV

Trial Locations (41)

10065

Memorial Sloan-Kettering Cancer Center, New York

12208

Women's Cancer Care Associates LLC, Albany

19001

Abington Memorial Hospital, Abington

19111

Fox Chase Cancer Center, Philadelphia

20010

Washington Hospital Center, Washington D.C.

24016

Carilion Clinic Gynecological Oncology, Roanoke

27157

Wake Forest University Health Sciences, Winston-Salem

27834

Gynecologic Oncology Network, Greenville

28203

Carolinas Medical Center, Charlotte

29621

AnMed Health Cancer Center, Anderson

31404

Memorial University Medical Center, Savannah

39216

University of Mississippi Medical Center, Jackson

43214

Riverside Methodist Hospital, Columbus

44109

MetroHealth Medical Center, Cleveland

46202

Indiana University Medical Center, Indianapolis

46260

Saint Vincent Hospital and Health Services, Indianapolis

46350

IU Health La Porte Hospital, La Porte

46515

Elkhart General Hospital, Elkhart

46601

Memorial Hospital of South Bend, South Bend

46617

South Bend Clinic, South Bend

46628

Northern Indiana Cancer Research Consortium, South Bend

46904

Community Howard Regional Health, Kokomo

49085

Lakeland Hospital, Saint Joseph

49546

Gynecologic Oncology of West Michigan PLLC, Grand Rapids

52242

University of Iowa Hospitals and Clinics, Iowa City

60521

Sudarshan K Sharma MD Limted-Gynecologic Oncology, Hinsdale

60612

Rush University Medical Center, Chicago

60637

University of Chicago, Chicago

63110

Saint Louis University Hospital, St Louis

Washington University School of Medicine, St Louis

64057

Centerpoint Medical Center LLC, Independence

64108

Truman Medical Center, Kansas City

65804

Mercy Hospital Springfield, Springfield

Ozark Health Ventures LLC-Cancer Research for The Ozarks Springfield, Springfield

73104

University of Oklahoma Health Sciences Center, Oklahoma City

74146

Tulsa Cancer Institute, Tulsa

06102

Hartford Hospital, Hartford

06050

The Hospital of Central Connecticut, New Britain

46545-1470

Saint Joseph Regional Medical Center-Mishawaka, Mishawaka

08103

Cooper Hospital University Medical Center, Camden

02905

Women and Infants Hospital, Providence

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

NRG Oncology

OTHER

lead

National Cancer Institute (NCI)

NIH

NCT00723255 - Bevacizumab and Temsirolimus in Treating Patients With Recurrent or Persistent Endometrial Cancer | Biotech Hunter | Biotech Hunter